First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease

Abstract The combination of rifamycin (RFP), ethambutol (EB), and macrolides is currently the standard regimen for treatment of Mycobacterium avium complex pulmonary disease (MAC-PD). However, poor adherence to the standardized regimens recommended by current guidelines have been reported. We undert...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Kiyoharu Fukushima, Seigo Kitada, Sho Komukai, Tomoki Kuge, Takanori Matsuki, Hiroyuki Kagawa, Kazuyuki Tsujino, Mari Miki, Keisuke Miki, Hiroshi Kida
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Nature Portfolio 2021-01-01
Σειρά:	Scientific Reports
Διαθέσιμο Online:	https://doi.org/10.1038/s41598-021-81025-w
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!